ValuEngine cut shares of Adaptimmune Therapeutics (NASDAQ:ADAP) from a buy rating to a hold rating in a report published on Tuesday morning.
Other analysts have also issued reports about the stock. Cowen reaffirmed a buy rating on shares of Adaptimmune Therapeutics in a research report on Wednesday, August 15th. Raymond James dropped their price target on shares of Adaptimmune Therapeutics from $20.00 to $16.00 and set a buy rating on the stock in a research report on Monday, October 22nd. BidaskClub raised shares of Adaptimmune Therapeutics from a hold rating to a buy rating in a research report on Saturday, September 29th. Guggenheim assumed coverage on shares of Adaptimmune Therapeutics in a research report on Monday, September 17th. They set a buy rating on the stock. Finally, Zacks Investment Research upgraded shares of Adaptimmune Therapeutics from a hold rating to a buy rating and set a $7.75 price objective on the stock in a report on Wednesday, October 24th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company’s stock. Adaptimmune Therapeutics has an average rating of Buy and an average target price of $15.44.
NASDAQ ADAP traded down $0.48 on Tuesday, hitting $6.18. 682,929 shares of the stock were exchanged, compared to its average volume of 795,120. Adaptimmune Therapeutics has a 52 week low of $5.73 and a 52 week high of $14.63. The firm has a market capitalization of $627.87 million, a P/E ratio of -7.73 and a beta of 2.02.
Adaptimmune Therapeutics (NASDAQ:ADAP) last posted its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.03) by $0.09. Adaptimmune Therapeutics had a negative net margin of 139.57% and a negative return on equity of 41.63%. The firm had revenue of $40.79 million for the quarter, compared to analyst estimates of $29.41 million. As a group, sell-side analysts expect that Adaptimmune Therapeutics will post -0.98 EPS for the current fiscal year.
In other Adaptimmune Therapeutics news, insider Gwendolyn Knowlt Binder-Scholl sold 25,000 shares of the company’s stock in a transaction on Wednesday, August 29th. The shares were sold at an average price of $10.25, for a total value of $256,250.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, major shareholder Enterprise Associates 14 New acquired 3,000,000 shares of the firm’s stock in a transaction on Friday, September 7th. The stock was bought at an average price of $1.67 per share, for a total transaction of $5,010,000.00. The disclosure for this purchase can be found here. 26.47% of the stock is owned by insiders.
Large investors have recently added to or reduced their stakes in the business. BNP Paribas Arbitrage SA acquired a new position in shares of Adaptimmune Therapeutics in the second quarter valued at about $122,000. BB&T Securities LLC acquired a new position in shares of Adaptimmune Therapeutics in the second quarter valued at about $128,000. Jane Street Group LLC acquired a new position in shares of Adaptimmune Therapeutics in the first quarter valued at about $168,000. Trexquant Investment LP acquired a new position in shares of Adaptimmune Therapeutics in the second quarter valued at about $178,000. Finally, Trellus Management Company LLC acquired a new position in shares of Adaptimmune Therapeutics in the second quarter valued at about $195,000. Hedge funds and other institutional investors own 58.99% of the company’s stock.
About Adaptimmune Therapeutics
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its platform enables in identifying cancer targets; finding and genetically engineering T-cell receptors (TCR); and producing TCR therapeutic candidates for administration to patients.
Featured Article: Understanding Market Liquidity
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.